Please login to the form below

Not currently logged in
Email:
Password:

Lixiana

This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Latest news

  • The business case for patient engagement The business case for patient engagement

    More notably, Lixiana users are far less likely to promote the drug than Xarelto or Pradaxa users, despite having a similar level of confidence in the drug as Xarelto users and ... Are Lixiana users missing the confidence that Xarelto and Eliquis users

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

  • Daiichi Sankyo cuts a swathe through US workforce Daiichi Sankyo cuts a swathe through US workforce

    The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics